Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07114315) titled 'A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer' on Aug. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Akeso
Condition:
Pancreatic Cancer
Intervention:
Drug: AK112
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 160
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07114315
Published by HT Digital Content Services with permis...